Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KVAC Stock Forecast 2026-2027
$12.20
Current Price
$67.18M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KVAC Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
KVAC Price Momentum
-0.5%
1 Week Change
+1.0%
1 Month Change
+7.9%
1 Year Change
+3.8%
Year-to-Date Change
-2.8%
From 52W High of $12.55
+8.4%
From 52W Low of $11.25
📊 TOP ANALYST CALLS
Did KVAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Keen Vision is one of their latest high-conviction picks.
Latest KVAC Stock Price Targets & Analyst Predictions
KVAC has shown a year-to-date change of 3.8% and a 1-year change of 7.9%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for KVAC. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KVAC Analyst Ratings
0
Buy
0
Hold
0
Sell
KVAC Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $12.20
Latest KVAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KVAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Keen Vision Acquisition Corp. (KVAC) Competitors
The following stocks are similar to Keen Vision based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Keen Vision Acquisition Corp. (KVAC) Financial Data
Keen Vision Acquisition Corp. has a market capitalization of $67.18M with a P/E ratio of 81.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +3.8%.
Valuation Metrics
Market Cap
$67.18M
Enterprise Value
$71.54M
P/E Ratio
81.3x
PEG Ratio
-0.9x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-83.8%
Financial Health
Cash/Price Ratio
+0.0%
Current Ratio
0.0x
Debt/Equity
0.8x
ROE
+3.8%
ROA
+3.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Keen Vision Acquisition Corp. (KVAC) Business Model
About Keen Vision Acquisition Corp.
What They Do
Facilitates mergers and acquisitions for companies.
Business Model
The company operates as a special purpose acquisition company (SPAC) by using its capital resources to identify and merge with promising businesses. It generates revenue primarily through successful mergers and acquisitions, which provide a faster route for private companies to access public markets.
Additional Information
As a blank check company, Keen Vision Acquisition Corp. does not engage in commercial operations but focuses on sectors with strong growth potential and technological advancements. Its strategic partnerships and expertise in navigating regulatory complexities position it as a key player in connecting innovative companies with necessary financial resources and market access.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Ka Chun Wong
Country
United States
IPO Year
2023
Website
www.kv-ac.comKeen Vision Acquisition Corp. (KVAC) Latest News & Analysis
Latest News
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
11 months ago
Quick Summary
Medera Inc. and its subsidiary Novoheart presented seven scientific abstracts at the 2025 ISSCR Annual Meeting, focusing on cardiovascular disease therapeutics and cardiac tissue engineering.
Why It Matters
Successful presentation of scientific abstracts enhances Medera Inc.'s credibility and visibility, potentially attracting investment and increasing stock value as it advances in cardiovascular therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
1 year ago
Quick Summary
Medera Inc. will present data from its Phase 1/2a MUSIC-HFpEF trial on gene therapy candidate SRD-002 for heart failure at the Heart Failure 2025 Congress in Belgrade, May 17-20.
Why It Matters
Medera Inc.'s upcoming presentation of trial data for its gene therapy candidate could influence stock prices, signaling potential advancements in cardiovascular treatment and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. presented updated results from its MUSIC-HFpEF Phase 1/2a trial of SRD-002, a gene therapy for cardiovascular diseases, at the 2025 HFpEF Summit in March.
Why It Matters
Medera's clinical trial results for SRD-002 could significantly impact its stock price and market perception, especially in the lucrative cardiovascular therapy sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. announced that the Data and Safety Monitoring Board approved the continuation of its MUSIC-HFrEF trial, allowing the transition from Phase 1b to Phase 2 for gene therapy SRD-001 in heart failure patients.
Why It Matters
Positive clinical trial results and DSMB clearance for Medera's gene therapy SRD-001 may boost investor confidence, indicating potential advancements in treatment for heart failure and future revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medera Inc. completed patient dosing in its MUSIC-HFrEF Phase 1/2a trial for the gene therapy SRD-001, targeting heart failure with reduced ejection fraction.
Why It Matters
Completion of patient dosing in Medera's clinical trial for SRD-001 signals progress in developing a novel treatment for heart failure, potentially impacting the company's valuation and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Novoheart has installed its CTScreen™ system at UMC Utrecht, enhancing cardiac disease modeling and therapy development. This could lead to future co-development projects in regenerative medicine.
Why It Matters
The installation of Novoheart's CTScreen™ at UMC Utrecht enhances cardiac research capabilities, potentially leading to innovative therapies and increased market opportunities for Medera Inc. and its subsidiaries.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KVAC Stock
What is Keen Vision Acquisition Corp.'s (KVAC) stock forecast for 2026?
Analyst forecasts for Keen Vision Acquisition Corp. (KVAC) are not currently available. The stock is trading at $12.20.
Is KVAC stock a good investment in 2026?
Analyst ratings for KVAC are not currently available. The stock is currently trading at $12.20. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KVAC stock?
Price predictions from Wall Street analysts for KVAC are not currently available. The stock is trading at $12.20.
What is Keen Vision Acquisition Corp.'s business model?
The company operates as a special purpose acquisition company (SPAC) by using its capital resources to identify and merge with promising businesses. It generates revenue primarily through successful mergers and acquisitions, which provide a faster route for private companies to access public markets.
What is the highest forecasted price for KVAC Keen Vision Acquisition Corp.?
Price targets from Wall Street analysts for KVAC are not currently available. The stock is trading at $12.20.
What is the lowest forecasted price for KVAC Keen Vision Acquisition Corp.?
Price targets from Wall Street analysts for KVAC are not currently available. The stock is trading at $12.20.
What is the overall KVAC consensus from analysts for Keen Vision Acquisition Corp.?
Analyst ratings for KVAC are not currently available. The stock is trading at $12.20.
How accurate are KVAC stock price projections?
Stock price projections, including those for Keen Vision Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 5, 2026 3:07 AM UTC